MetaVia Inc. (MTVA:NASDAQ) closed at $1.23 on October 19, 2026, down 2.38% on the day. The stock trades 91.7% below its 52-week high of $14.85 and 27.3% above its 52-week low of $0.966. Over the past year, it lost 89.0%. MetaVia Inc. is part of the Health Care sector.
In 252 trading sessions since October 17, 2025, MTVA closed higher on 99 days (39%). Its best day was May 19, 2026 (+69.37%) and its worst was January 15, 2026 (-39.11%). The stock moved 10% or more in a single session 31 times. It opened at least 5% above the previous day's high 4 times.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.
Find more stocks like MTVA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.